Curium has signed a technology license agreement with Eczacıbaşı-Monrol Nuclear Products granting Curium access to noncarrier-added lutetium-177 technology.
The company will fund associated capital to build a production facility of 15000 Ci per annum on its Petten site in the Netherlands.
In October 2021, the firm started its Eclipse phase three registration trial for its proprietary LuPSMA in the treatment of patients with metastatic castration-resistant prostate cancer.
Curium said the addition of lutetium-177 for therapeutic use will build on the company's production of reactor-based isotopes.
